May Lead to New Treatments for Brain Cancer
GOLDEN, Colo.--(Business Wire)--
Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances
in its adult stem cell products and technology with application to cell-based
therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer,
we are reminded of such aggressive cancers without effective treatment.
Cancer stem cells are thought to generate cancerous tumors, and while some of
these tumor cells are destroyed by chemotherapy and radiation, cancer stem cells
resist these treatments causing recurrences and metastasis of cancer following
standard therapy. For example, glioblastoma tumors underlying Senator Kennedy`s
brain cancer may arise from cancer stem cells that resist conventional
treatments. Additional research shows that certain adult stem cells migrate to
cancer stem cells and may be used to carry toxic agents to selectively eradicate
cancer stem cells thereby providing novel cellular therapy specifically targeted
to cancer-causing cells. Further development of stem cell therapy may allow
treatment of presently untreatable cancer and also have more widespread
applications to prevention and treatment of cancer.
Vitro`s proprietary stem cell technology and products, now subject to pending
patent protection, may lead to novel cell therapy for cancer. The Company is
pursuing suitable strategic partners to commercialize these novel therapeutic
products. Furthermore, the Company has also commercialized various modified stem
cell lines and related products to support cancer stem cell research including
the development of new methods to target the selective eradication of cancer
stem cells, which is essential to therapeutic efficacy. These products and other
tools for use in stem cell research are now commercially available
(http://www.vitrobiopharma.com/).
Dr. Rice, a member of Vitro`s SAB and a University of Colorado cancer researcher
said, "Cellular-mediated destruction of cancer stem cells represents a promising
new avenue for the development of effective treatments that specifically target
cancer stem cells. Vitro has developed an exciting portfolio of products to
advance research in this field, which is one of the few approaches to show
promise against intractable cancers such as most forms of brain cancer.
Additionally, Vitro`s patent pending technology for cancer therapy represents an
exciting and novel approach to the selective eradication of cancer stem cells
that could usher in new promise in the fight against cancer."
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG)
(http://www.vitrobiopharma.com), known for "Harnessing the Power of Cells" owns
U.S. patents for production of the fertility drug, FSH, immortalization of
cells, and adult stem cells. The Company also owns a pending U.S. patent
regarding stem cell-based cancer treatments and is continuously developing newly
patentable cell lines and technologies. Vitro recently established a new high
tech and regulatory compliant manufacturing, R&D and corporate facility in
Golden, Colorado. The current focus is "Tools for Stem Cell and Drug
Development", a series of commercially available products for use in stem cell
research and drug development targeting human mesenchymal stem cells, induced
pluripotent stem cells and stem cell-based cancer research. In addition, Vitro`s
stem cell technology has shown promise for development of stem cell therapy for
diabetes and cancer.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on
behalf of the Company, whether oral or written may contain "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward looking statements are identified by words such as
"intends," "anticipates," "believes," "expects" and "hopes" and include, without
limitation, statements regarding the Company`s plan of business operations,
product research and development activities, potential contractual arrangements,
receipt of working capital, anticipated revenues and related expenditures.
Factors that could cause actual results to differ materially include, among
others, acceptability of the Company`s products in the market place, general
economic conditions, receipt of additional working capital, the overall state of
the biotechnology industry and other factors set forth in the Company`s filings
with the Securities and Exchange Commission. Most of these factors are outside
the control of the Company. Investors are cautioned not to put undue reliance on
forward-looking statements. Except as otherwise required by applicable
securities statutes or regulations, the Company disclaims any intent or
obligation to update publicly these forward looking statements, whether as a
result of new information, future events or otherwise.
Vitro Diagnostics, Inc.
Dr. James Musick, 303-999-2130
Chief Executive Officer
jim@vitrodiag.com
or
MEDIA CONTACT:
SK Helsel & Associates
Sandra Kay Helsel, Ph.D., 520-325-4636
Cell: 520-390-8184
skhelsel@skhelsel.com
Copyright Business Wire 2009
